Veracyte Inc (VCYT)
22.88
-0.52
(-2.22%)
USD |
NASDAQ |
May 17, 16:00
22.88
0.00 (0.00%)
After-Hours: 20:00
Veracyte Cash from Financing (Quarterly): -0.864M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.864M |
| December 31, 2023 | 0.645M |
| September 30, 2023 | 0.11M |
| June 30, 2023 | 0.397M |
| March 31, 2023 | 1.685M |
| December 31, 2022 | 0.093M |
| September 30, 2022 | 1.486M |
| June 30, 2022 | -0.075M |
| March 31, 2022 | 1.99M |
| December 31, 2021 | 0.173M |
| September 30, 2021 | 3.215M |
| June 30, 2021 | 1.92M |
| March 31, 2021 | 591.01M |
| December 31, 2020 | 2.911M |
| September 30, 2020 | 197.51M |
| June 30, 2020 | 3.39M |
| March 31, 2020 | -0.219M |
| December 31, 2019 | 2.965M |
| September 30, 2019 | 4.797M |
| June 30, 2019 | 127.92M |
| March 31, 2019 | -8.394M |
| December 31, 2018 | 1.829M |
| September 30, 2018 | 56.53M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.239M |
| March 31, 2018 | 0.901M |
| December 31, 2017 | -1.188M |
| September 30, 2017 | 0.442M |
| June 30, 2017 | -0.02M |
| March 31, 2017 | 0.548M |
| December 31, 2016 | 32.20M |
| September 30, 2016 | 0.317M |
| June 30, 2016 | -0.135M |
| March 31, 2016 | 19.94M |
| December 31, 2015 | -0.012M |
| September 30, 2015 | -0.004M |
| June 30, 2015 | 37.66M |
| March 31, 2015 | 0.092M |
| December 31, 2014 | -0.019M |
| September 30, 2014 | 0.109M |
| June 30, 2014 | 0.448M |
| March 31, 2014 | -0.102M |
| December 31, 2013 | 59.36M |
| September 30, 2013 | 0.101M |
| June 30, 2013 | 18.00M |
| March 31, 2013 | 0.195M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.864M
Minimum
Mar 2024
591.01M
Maximum
Mar 2021
47.05M
Average
1.802M
Median
Cash from Financing (Quarterly) Benchmarks
| Fonar Corp | -1.761M |
| XWELL Inc | 0.00 |
| ProPhase Labs Inc | 2.271M |
| Applied DNA Sciences Inc | 3.015M |
| OncoCyte Corp | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.966M |
| Cash from Investing (Quarterly) | 2.878M |
| Free Cash Flow | 26.33M |
| Free Cash Flow Per Share (Quarterly) | -0.1485 |
| Free Cash Flow to Equity (Quarterly) | -11.10M |
| Free Cash Flow to Firm (Quarterly) | -11.10M |
| Free Cash Flow Yield | 1.57% |